Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Tallerico

Orthopaedic Surgery Fort Mill, SC Doctor of Osteopathy

NPI 1538137724 CMS profile 976433

986 Wellness Way Ste 300, Fort Mill, SC 29715

Open in the dashboard

General payments

$12,646

214 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Tallerico of Fort Mill, SC is reported in the CMS Open Payments database as having received $12,646 across 214 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $395 7
2024 General $1,802 18
2023 General $1,478 33
2022 General $2,684 67
2021 General $2,780 43
2020 General $465 15
2019 General $3,042 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Tallerico
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Brian Tallerico were reported at $395. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Brian Tallerico Orthopaedic Surgery median Middle half National median
2019 $3,042 $644 $140–$2,844 $163
2020 $465 $312 $75–$1,860 $114
2021 $2,780 $520 $117–$2,495 $132
2022 $2,684 $598 $128–$2,731 $149
2023 $1,478 $461 $128–$2,264 $160
2024 $1,802 $497 $134–$2,475 $164
2025 $395 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $4,106 104 payments
  2. Medacta USA, Inc. $2,262 9 payments
  3. Prodigy Surgical Distribution, Inc. $1,304 2 payments
  4. SI-BONE, Inc. $1,298 14 payments
  5. Smith+Nephew, Inc. $863 20 payments
  6. Catalyst OrthoScience $816 4 payments
  7. Pacira Pharmaceuticals Incorporated $348 9 payments
  8. Peerless Surgical Inc. $317 3 payments
  9. LifeNet Health $125 1 payment
  10. Heron Therapeutics, Inc. $125 1 payment
  11. Other $1,082 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,833 209 payments
  2. Travel and Lodging $2,094 3 payments
  3. Education $1,200 1 payment
  4. Consulting Fee $519 1 payment
Products named General payments · program years 2019–2025
  1. MAKO $2,364 54 payments
  2. GMK $1,047 2 payments
  3. GMK SPHERE $953 2 payments
  4. Catalyst CSR Shoulder System Orthopedic $519 1 payment
  5. TRIATHLON $315 12 payments
  6. Catalyst CSR Shoulder System Orthopedics $297 3 payments
  7. Bone Anchors with Arthroscopic Delivery System $262 4 payments
  8. R1 Reverse Shoulder System $226 2 payments
  9. LEGION Revision $212 2 payments
  10. GMK REVISION $206 3 payments
  11. Other $4,283 146 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$57,837

Of which drugs: $460

Medicare patients

140

Average age 74

Services billed

1,256

90 women, 50 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Depression 33%
Ischemic heart disease 27%
Diabetes 25%
Osteoporosis 25%
Alzheimer's or dementia 19%
Chronic kidney disease 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 15 816 $78

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

214 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record